ID

44514

Descripción

Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab in Subjects With Advanced Liver Cancer Anti-PD-1 HCC (Anti-Programmed-Death-1 Hepatocellular Carcinoma); ODM derived from: https://clinicaltrials.gov/show/NCT01658878

Link

https://clinicaltrials.gov/show/NCT01658878

Palabras clave

Versiones (2)
  1. 20/2/20 20/2/20 -
  2. 27/9/21 27/9/21 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

27 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Hepatocellular Carcinoma NCT01658878

Inglés

Eligibility Hepatocellular Carcinoma NCT01658878

1 formularios  
Criteria
Descripción

Criteria

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
subjects of 18 years or older (men and women) with histological confirmation of advanced hepatocellular carcinoma
Descripción

Age | Liver carcinoma Advanced

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2,1]
C2239176
UMLS CUI [2,2]
C0205179
eastern cooperative oncology group (ecog) performance status of 0 to 1
Descripción

ECOG performance status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
for the dose escalation cohorts (uninfected, hcv-infected, and hbv-infected): subjects must have progressive disease following or be intolerant of at least one line of systemic therapy or refuse sorafenib treatment
Descripción

Dose Escalation Cohort | Infection Absent | Hepatitis C | Hepatitis B | Progressive Disease | Intolerance Systemic therapy Quantity | Sorafenib Refused

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3816728
UMLS CUI [1,2]
C0599755
UMLS CUI [2,1]
C3714514
UMLS CUI [2,2]
C0332197
UMLS CUI [3]
C0019196
UMLS CUI [4]
C0019163
UMLS CUI [5]
C1335499
UMLS CUI [6,1]
C0231199
UMLS CUI [6,2]
C1515119
UMLS CUI [6,3]
C1265611
UMLS CUI [7,1]
C1516119
UMLS CUI [7,2]
C1705116
for the uninfected sorafenib naive or intolerant hcc expansion cohort, subjects must either never have received sorafenib treatment or were intolerant to sorafenib therapy
Descripción

Infection Absent | Sorafenib Absent | Intolerance to Sorafenib | Liver carcinoma Expansion

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3714514
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C1516119
UMLS CUI [2,2]
C0332197
UMLS CUI [3,1]
C1744706
UMLS CUI [3,2]
C1516119
UMLS CUI [4,1]
C2239176
UMLS CUI [4,2]
C1519678
for the uninfected sorafenib failure hcc expansion cohort, subjects must have had documented radiographic or symptomatic progression during or after sorafenib therapy
Descripción

Infection Absent | Sorafenib failed | Liver carcinoma Expansion | Disease Progression Radiography | Disease Progression Symptomatic

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3714514
UMLS CUI [1,2]
C0332197
UMLS CUI [2,1]
C1516119
UMLS CUI [2,2]
C0231175
UMLS CUI [3,1]
C2239176
UMLS CUI [3,2]
C1519678
UMLS CUI [4,1]
C0242656
UMLS CUI [4,2]
C0043299
UMLS CUI [5,1]
C0242656
UMLS CUI [5,2]
C0231220
dose escalation phase: child-pugh score of 7 points or less, i.e., child-pugh a or child pugh b7
Descripción

Dose Escalation Phase | Child-Pugh Score | Child-Pugh Classification

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C3816728
UMLS CUI [1,2]
C1710475
UMLS CUI [2]
C4055253
UMLS CUI [3]
C4050412
expansion phase: child-pugh score of 6 points or less, i.e., child-pugh a
Descripción

Expansion Phase | Child-Pugh Score | Child-Pugh Classification

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1519678
UMLS CUI [1,2]
C1710475
UMLS CUI [2]
C4055253
UMLS CUI [3]
C4050412
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
subjects with brain metasteses
Descripción

Metastatic malignant neoplasm to brain

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0220650
any prior or current clinically significant ascites as measured by physical examination and that requires active parancentesis for control
Descripción

Ascites Physical Examination | Paracentesis Required

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003962
UMLS CUI [1,2]
C0031809
UMLS CUI [2,1]
C0034115
UMLS CUI [2,2]
C1514873
any history of clinically meaningful variceal bleeding within the last three months
Descripción

Bleeding varices

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0333106
active coinfection with both hepatitis b and c
Descripción

HBV coinfection | HCV coinfection

Tipo de datos

boolean

Alias
UMLS CUI [1]
C2242656
UMLS CUI [2]
C1698259
hepatitis d infection in subjects with hepatitis b
Descripción

Hepatitis D Infection In addition to Hepatitis B

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0011226
UMLS CUI [1,2]
C0332287
UMLS CUI [1,3]
C0019163
Volver a la parte superior de la página

Similar models

Eligibility Hepatocellular Carcinoma NCT01658878

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Item Group
C1512693 (UMLS CUI)
Age | Liver carcinoma Advanced
Item
subjects of 18 years or older (men and women) with histological confirmation of advanced hepatocellular carcinoma
boolean
C0001779 (UMLS CUI [1])
C2239176 (UMLS CUI [2,1])
C0205179 (UMLS CUI [2,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0 to 1
boolean
C1520224 (UMLS CUI [1])
Dose Escalation Cohort | Infection Absent | Hepatitis C | Hepatitis B | Progressive Disease | Intolerance Systemic therapy Quantity | Sorafenib Refused
Item
for the dose escalation cohorts (uninfected, hcv-infected, and hbv-infected): subjects must have progressive disease following or be intolerant of at least one line of systemic therapy or refuse sorafenib treatment
boolean
C3816728 (UMLS CUI [1,1])
C0599755 (UMLS CUI [1,2])
C3714514 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0019196 (UMLS CUI [3])
C0019163 (UMLS CUI [4])
C1335499 (UMLS CUI [5])
C0231199 (UMLS CUI [6,1])
C1515119 (UMLS CUI [6,2])
C1265611 (UMLS CUI [6,3])
C1516119 (UMLS CUI [7,1])
C1705116 (UMLS CUI [7,2])
Infection Absent | Sorafenib Absent | Intolerance to Sorafenib | Liver carcinoma Expansion
Item
for the uninfected sorafenib naive or intolerant hcc expansion cohort, subjects must either never have received sorafenib treatment or were intolerant to sorafenib therapy
boolean
C3714514 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1516119 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C1744706 (UMLS CUI [3,1])
C1516119 (UMLS CUI [3,2])
C2239176 (UMLS CUI [4,1])
C1519678 (UMLS CUI [4,2])
Infection Absent | Sorafenib failed | Liver carcinoma Expansion | Disease Progression Radiography | Disease Progression Symptomatic
Item
for the uninfected sorafenib failure hcc expansion cohort, subjects must have had documented radiographic or symptomatic progression during or after sorafenib therapy
boolean
C3714514 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C1516119 (UMLS CUI [2,1])
C0231175 (UMLS CUI [2,2])
C2239176 (UMLS CUI [3,1])
C1519678 (UMLS CUI [3,2])
C0242656 (UMLS CUI [4,1])
C0043299 (UMLS CUI [4,2])
C0242656 (UMLS CUI [5,1])
C0231220 (UMLS CUI [5,2])
Dose Escalation Phase | Child-Pugh Score | Child-Pugh Classification
Item
dose escalation phase: child-pugh score of 7 points or less, i.e., child-pugh a or child pugh b7
boolean
C3816728 (UMLS CUI [1,1])
C1710475 (UMLS CUI [1,2])
C4055253 (UMLS CUI [2])
C4050412 (UMLS CUI [3])
Expansion Phase | Child-Pugh Score | Child-Pugh Classification
Item
expansion phase: child-pugh score of 6 points or less, i.e., child-pugh a
boolean
C1519678 (UMLS CUI [1,1])
C1710475 (UMLS CUI [1,2])
C4055253 (UMLS CUI [2])
C4050412 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
Metastatic malignant neoplasm to brain
Item
subjects with brain metasteses
boolean
C0220650 (UMLS CUI [1])
Ascites Physical Examination | Paracentesis Required
Item
any prior or current clinically significant ascites as measured by physical examination and that requires active parancentesis for control
boolean
C0003962 (UMLS CUI [1,1])
C0031809 (UMLS CUI [1,2])
C0034115 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
Bleeding varices
Item
any history of clinically meaningful variceal bleeding within the last three months
boolean
C0333106 (UMLS CUI [1])
HBV coinfection | HCV coinfection
Item
active coinfection with both hepatitis b and c
boolean
C2242656 (UMLS CUI [1])
C1698259 (UMLS CUI [2])
Hepatitis D Infection In addition to Hepatitis B
Item
hepatitis d infection in subjects with hepatitis b
boolean
C0011226 (UMLS CUI [1,1])
C0332287 (UMLS CUI [1,2])
C0019163 (UMLS CUI [1,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial